Federal Register of Legislation - Australian Government

Primary content

Directions/Other as made
This direction provides written directions from the responsible Ministers to the Future Fund Board of Guardians about the performance of the Medical Research Future Fund investment functions.
Administered by: Finance
Exempt from sunsetting by the Legislation Act 2003 s 54(1), Legislation Act 2003 s 54(2)(c)
Made 08 Nov 2015
Registered 19 Nov 2015
Tabled HR 23 Nov 2015
Tabled Senate 23 Nov 2015

 

 

 

Medical Research Future Fund

Investment Mandate Direction 2015                                                 

 

We, SCOTT JOHN MORRISON, Treasurer, and MATHIAS HUBERT PAUL CORMANN, Minister for Finance, give this Direction under subsection 39(1) of the Medical Research Future Fund Act 2015.

 

Dated              8 - 11 - 2015

 

 

 

 

 

SCOTT JOHN MORRISON                         MATHIAS HUBERT PAUL CORMANN

  Treasurer                                                             Minister for Finance                                         


 

 

Part 1      Preliminary

 

 

1.      Name of Direction                                        

 

This Direction is the Medical Research Future Fund Investment Mandate Direction 2015.

 

2.      Commencement

 

This Direction commences on the 15th day after it is given.

 

   Note:      Section 42 of the Legislative Instruments Act 2003 (which deals with the disallowance of legislative instruments) does not apply to this instrument: see section 44 of that Act. Part 6 of that Act (which deals with the sunsetting of legislative instruments) does not apply to this instrument: see section 54 of that Act.

 

3.      Definitions

 

In this Direction:

 

Act means the Medical Research Future Fund Act 2015.

 

Board means the Future Fund Board of Guardians.

 

Fund means the Medical Research Future Fund.

 

responsible Ministers has the same meaning as in the Act.

 

4.      Object of this Direction

 

The Fund has been established to provide grants of financial assistance to support medical research and medical innovation over the long term.

 

The object of this Direction is to give guidance to the Board in relation to its investment strategy for the Fund. The Board is required under section 40 of the Act to:

·         seek to maximise the return earned on the Fund over the long term, consistent with international best practice for institutional investment; and

·         to enhance the commonwealth’s ability to provide grants of financial assistance to support medical research and innovation,

subject to its obligations under the Act and any directions given by the responsible Ministers under the Act.

 

This Direction is given under subsection 39(1) of the Act to articulate the Government’s expectations for how the Fund will be invested and managed by the Board.


 

 

Part 2      Direction

 

 

5.      Benchmark return

 

The Board is to adopt an average return of at least the Reserve Bank of Australia Cash Rate target + 1.5 to 2.0 per cent per annum, net of investment fees, over a rolling 10 year term as the benchmark return on the Fund.

In targeting the benchmark return, the Board must determine an acceptable but not excessive level of risk for the Fund measured in terms such as the probability of losses in a particular year. In determining the level of risk, the Board must take into account:

·         the principle that the nominal value of the credits to the Fund be preserved over the long term; and

·          the principle to moderate the volatility of the maximum annual distribution.

 

6.      Board must consider impacts from its investment strategy

 

In undertaking its investment activities, the Board must act in a way that:

 

(a) minimises the potential to effect any abnormal change in the volatility or efficient operation of Australian financial markets; and

(b) is unlikely to cause any diminution of the Australian Government’s reputation in Australian and international financial markets.

 

7.      Corporate Governance

 

The Board must have regard to international best practice for institutional investment in determining its approach to corporate governance principles, including in relation to its voting policy.